Goldman Sachs
CSBR icon

Goldman Sachs’s Champions Oncology CSBR Stock Holding History

Goldman Sachs’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,129
Closed -$201K – 6123
2025
Q1 		$201K Buy
+23,129
New +$234K ﹤0.01% 5642
2024
Q4 		– Sell
-48,413
Closed -$236K – 6063
2024
Q3 		$236K Sell
48,413
-20,891
-30% -$98K ﹤0.01% 5395
2024
Q2 		$358K Buy
69,304
+3
+0% +$15 ﹤0.01% 5006
2024
Q1 		$340K Buy
+69,301
New +$406K ﹤0.01% 4919
2017
Q1 		– Sell
-50,072
Closed -$127K – 6788
2016
Q4 		$127K Sell
50,072
-16,230
-24% -$31.6K ﹤0.01% 6024
2016
Q3 		$111K Buy
+66,302
New +$123K ﹤0.01% 6179

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's CSBR Position: Q2 2025 in Review

Goldman Sachs sold out of Champions Oncology (CSBR) in Q2 2025, closing a stake of 23,129 shares — an estimated $201K sold.

Goldman Sachs first reported a position in CSBR in Q3 2016 and held it in 6 quarters. The position peaked at $358K in Q2 2024. 30 funds tracked by Wall St. Rank hold CSBR as of Q2 2025.

  • Goldman Sachs reported no remaining Champions Oncology position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 23,129 Champions Oncology shares in Q2 2025, an estimated $201K.
  • Goldman Sachs first reported a position in Champions Oncology in Q3 2016 and held it in 6 quarters.
  • Goldman Sachs's Champions Oncology position peaked at $358K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.